---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088823"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:58:26.587982+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q2 net loss $8.4M, revenue $17.2M; DFD-29 Phase 3 positive, NDA submission H2 2023

## Summary
- Q2 2023 net revenues $17.2M, down 6% YoY but up 41% QoQ; core product revenue grew 19% YoY to $15.6M (92% of total).
- GAAP net loss $8.4M ($0.46/sh) vs $7.5M loss ($0.43/sh) in Q2 2022; adjusted EBITDA improved to -$0.6M from -$2.6M.
- DFD-29 Phase 3 trials met co-primary and all secondary endpoints, superior to placebo and Oracea; NDA submission planned H2 2023.
- Non-cash impairment of Ximino intangible asset of $3.1M; SG&A down 20% to $12.1M from cost reduction initiatives.

## SEC filing metadata
- accession: 0001104659-23-088823
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/0001104659-23-088823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/tm2323104d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088823
- JSON: https://secwatch.observer/filing/0001104659-23-088823.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088823.txt

## Key facts
- Earnings Releases
  Journey Medical Corp reported the second quarter ended June 30, 2023 results: revenue $17.2 million, net income GAAP net loss was $8.4 million, or $0.46 per share basic and diluted, EPS $0.46 per share basic and diluted.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $17.2 million
  - Net income: GAAP net loss was $8.4 million, or $0.46 per share basic and diluted
  - EPS: $0.46 per share basic and diluted
  - Result: reported results
  source text: EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/0001104659-23-088823-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.